| 1 |
34268530 | An update on acalabrutinib to treat chronic lymphocytic leukemia. | 2021 Jul |
1 |
| 2 |
34275396 | Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. | 2021 Sep |
1 |
| 3 |
31915195 | Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. | 2020 Mar |
1 |
| 4 |
33093947 | ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. | 2020 |
1 |
| 5 |
30089638 | Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. | 2018 Oct |
1 |
| 6 |
28642301 | The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. | 2017 Oct |
1 |